By Business/Source
Currency:USD
2026/Q1
Stock NameRevenueRatio
FILSPARI105.15M82.67%
Tiopronin products19.34M15.20%
License and collaboration revenue2.71M2.13%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States490.73M100.00%